Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANDEM: Safety of Concomitant Ubrogepant and Atogepant in Migraine
NCT05264129Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ubrogepant in migraine, sponsored by AbbVie Inc.. Started Mar 2022; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05264129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264129.